[
  {
    "ts": null,
    "headline": "Why I Sold Pfizer To Buy Novo Nordisk",
    "summary": "While Pfizer's market cap and dividends are at risk, Novo has a strong competitive position in GLP-1 TAM. Read why I prefer NVO stock over PFE stock.",
    "url": "https://finnhub.io/api/news?id=40b515a4da8101ca2797023064ae8b857503c444098b8d518d8f6feb5be015b6",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757822229,
      "headline": "Why I Sold Pfizer To Buy Novo Nordisk",
      "id": 136739947,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2158305291/image_2158305291.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "While Pfizer's market cap and dividends are at risk, Novo has a strong competitive position in GLP-1 TAM. Read why I prefer NVO stock over PFE stock.",
      "url": "https://finnhub.io/api/news?id=40b515a4da8101ca2797023064ae8b857503c444098b8d518d8f6feb5be015b6"
    }
  }
]